Foresee pharma
Annual shareholders' meeting notice describing corporate governance actions, financial reporting and audit items, and a proposal to authorize the board to issue up to 35,000,000 common shares via cash capital increase (including private placement, book-building, auction) to raise working capital and improve financial flexibility. The notice details pricing mechanics, investor selection criteria, regulatory disclosures, proxy and electronic voting procedures, and post-issuance listing options subject to applicable securities rules.
Industries
Nr. of Employees
medium (51-250)
Foresee pharma
Products
CAMCEVI 42 mg
CAMCEVI 42 mg is a gonadotropin-releasing hormone (GnRH) agonist prefilled syringe injectable emulsion administered subcutaneously every 6 months for advanced prostate cancer.
SIF
Proprietary Stabilized Injectable Formulation (SIF) sustained-release drug delivery platform for long-acting injectable products.
FP-014 (Triptorelin)
FP-014 is a ready-to-use, subcutaneous, long-acting injectable dosage form of triptorelin administered every three or six months for advanced or metastatic prostate cancer and other conditions.
FP-001 42 mg
A stabilized injectable formulation depot injection for central precocious puberty.
linvemastat (FP-020)
An oral small molecule MMP-12 inhibitor follow-on compound currently in development for asthma, inflammatory bowel disease, and chronic obstructive pulmonary disease.
mirivadelgat (FP-045)
An oral small molecule ALDH2 activator candidate currently in development for pulmonary hypertension associated with interstitial lung disease.
CAMCEVI 42 mg
CAMCEVI 42 mg is a gonadotropin-releasing hormone (GnRH) agonist prefilled syringe injectable emulsion administered subcutaneously every 6 months for advanced prostate cancer.
SIF
Proprietary Stabilized Injectable Formulation (SIF) sustained-release drug delivery platform for long-acting injectable products.
FP-014 (Triptorelin)
FP-014 is a ready-to-use, subcutaneous, long-acting injectable dosage form of triptorelin administered every three or six months for advanced or metastatic prostate cancer and other conditions.
FP-001 42 mg
A stabilized injectable formulation depot injection for central precocious puberty.
linvemastat (FP-020)
An oral small molecule MMP-12 inhibitor follow-on compound currently in development for asthma, inflammatory bowel disease, and chronic obstructive pulmonary disease.
mirivadelgat (FP-045)
An oral small molecule ALDH2 activator candidate currently in development for pulmonary hypertension associated with interstitial lung disease.
Expertise Areas
- Corporate finance and capital raising
- Securities regulatory compliance and disclosures
- Shareholder meeting and proxy administration
- Financial reporting and audit governance
Key Technologies
- Dematerialized securities (electronic share registry)
- Electronic shareholder voting platforms
- Regulatory and market disclosure portals
- Stock transfer agency systems
News & Updates
Notice of the annual shareholders' meeting scheduled for May 21, 2026, including agenda items and procedural details.
Notice of the annual shareholders' meeting scheduled for May 21, 2026, including agenda items and procedural details.